A nanodrug comprising low-molecular-weight heparin and QU has been reported to target basic fibroblast growth factor and VEGF , inhibit drug efflux protein expression ( P-gp , MRP1 , and BCRP ), and prevent drug resistance in breast cancer 80 ( Table 1 )
Wharton S, Kuk JL, Luszczynski M, Kamran E, Christensen RAG
Agarwal A, Dadge SD, Garg R, Chauhan D, Katekar R, Maity D, et al
This work was supported by the Foundation for Research in Rheumatology (FOREUM)
Additionally, targeting intracellular GSH levels is a compelling antitumor strategy due to heightened GSH levels in cancer cells to counteract oxidative stress
More information Find out more about how GLP-1 medicines work at the Cleveland Clinic